Risk of subsequent primary lymphoma in a cohort of 69,460 five-year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study.

"CONFLICTS OF INTEREST Zsuzsanna Jakab reports personal fees from Semmelweis Egyetem outside the submitted work. Lars Hjorth reports personal fees from Bayer and F. Hoffmann‐La Roche outside the submitted work. The remaining authors made no disclosures."

"The authors are very grateful to the childhood cancer survivors whose information was used in this data set. The authors thank the following individuals from each country for their contribution to data preparation: France: Angela Jackson, Florent Dayet, Amar Kahlouche, Fara Diop, Sylvie Challeton, Martine Labbé, and Isao Kobayashi; Italy: the Italian Association of Pediatric Hematology and Oncology–Off Therapy Registry Group, Maura Massimino, Silvia Caruso, Monica Muraca, Vera Morsellino, Claudia Casella, Lucia Miligi, Anita Andreano, Andrea Biondi, and the Italian Association of Cancer Registries Working Group; Netherlands: Dutch Childhood Oncology Group LATER, Wim Tissing, Marry van den Heuvel‐Eibrink, Eline van Dulmen, Dorine Bresters, and Birgitta Versluys; Slovenia: Tina Žagar; Sweden: Ingemar Andersson and Susanne Nordenfelt; Switzerland: Elisabeth Kiraly, Vera Mitter, Shelagh Redmond, and the Swiss Pediatric Oncology Group (www.spog.ch); United Kingdom: Julie Kelly. Author Isabelle M. Dudley also thanks the Arthur Thomson Trust at the University of Birmingham for their financial support and interest in this project. The PanCareSurFup consortium and related work was supported by the European Union’s Seventh Framework Programme for research, technological development, and demonstration under grant agreement no. 257505. Additional financial support was received from: the Foundation Force de Recherche sur le Cancer de l’Enfant, The Italian Association for Cancer Research and the Compagnia San Paolo, the Fondo Chiara Rama ONLUS, the Swedish Childhood Cancer Fund, the French Association for Cancer Research, the French National Agency for Research (Hope‐Epi project), the French National Cancer Institute, Pfizer Foundation for Children and Adolescent Health, the Slovenian Research Agency, the Swiss Paediatric Oncology Group, the Swiss Cancer League (KLS‐3412‐02‐2014, KLS‐3886‐02‐2016, and KLS‐5432‐08‐2021), the Swiss Cancer Research Foundation (KFS‐02783‐02‐2011, KFS‐4157‐02‐2017, KLA/KFS‐4825‐01‐2019, KFS‐4722‐02‐2019, and KFS‐5302‐02‐2021), the Swiss National Science Foundation (PDFMP3_141775), the Dutch Cancer Society (DCOG2011‐5027 and UVA2012‐5517), the Norwegian Childhood Cancer Foundation, and Children with Cancer UK (grant no: 20457)."